Last reviewed · How we verify
CM082 combined with everolimus
CM082 is a tyrosine kinase inhibitor that targets multiple kinases including VEGFR and FLT3, combined with everolimus (an mTOR inhibitor) to provide dual pathway inhibition for cancer treatment.
CM082 is a tyrosine kinase inhibitor that targets multiple kinases including VEGFR and FLT3, combined with everolimus (an mTOR inhibitor) to provide dual pathway inhibition for cancer treatment. Used for Renal cell carcinoma, Other solid tumors (under investigation in Phase 3).
At a glance
| Generic name | CM082 combined with everolimus |
|---|---|
| Also known as | X-82, Affinitor |
| Sponsor | AnewPharma |
| Drug class | Tyrosine kinase inhibitor + mTOR inhibitor combination |
| Target | VEGFR, FLT3, mTOR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CM082 inhibits receptor tyrosine kinases involved in angiogenesis and tumor cell proliferation, while everolimus blocks mTOR signaling to suppress cell growth and survival. The combination targets both growth factor signaling and metabolic pathways to enhance anti-tumor efficacy.
Approved indications
- Renal cell carcinoma
- Other solid tumors (under investigation in Phase 3)
Common side effects
- Hypertension
- Diarrhea
- Fatigue
- Mucositis
- Thrombocytopenia
- Anemia
Key clinical trials
- CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma (PHASE3)
- Study of the Combination of CM082 With Everolimus in Patients With mRCC (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CM082 combined with everolimus CI brief — competitive landscape report
- CM082 combined with everolimus updates RSS · CI watch RSS
- AnewPharma portfolio CI